达安基因
(002030)
| 流通市值：81.96亿 | | | 总市值：81.96亿 |
| 流通股本：14.03亿 | | | 总股本：14.03亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 327,825,993.97 | 149,439,274.94 | 757,661,908.2 | 503,506,935.73 |
| 营业收入 | 327,825,993.97 | 149,439,274.94 | 757,661,908.2 | 503,506,935.73 |
| 二、营业总成本 | 434,890,916.9 | 205,156,295.51 | 1,054,914,863.88 | 720,643,863.72 |
| 营业成本 | 216,974,272.09 | 103,461,238.33 | 512,169,253.84 | 339,024,438.37 |
| 税金及附加 | 2,583,880.14 | 1,676,744.15 | 11,315,791.69 | 3,449,721.87 |
| 销售费用 | 100,689,557.39 | 44,959,591.77 | 223,443,468.66 | 157,727,422.3 |
| 管理费用 | 66,083,011.2 | 32,096,140.94 | 157,816,213.49 | 104,168,144.62 |
| 研发费用 | 54,831,028.68 | 25,675,716.86 | 186,342,770.58 | 145,883,697.34 |
| 财务费用 | -6,270,832.6 | -2,713,136.54 | -36,172,634.38 | -29,609,560.78 |
| 其中:利息费用 | 2,350,762.09 | 1,084,180.24 | 4,185,770.56 | 2,752,671.58 |
| 其中:利息收入 | 20,327,504.72 | 10,257,718.49 | 48,225,798.79 | 37,460,940.92 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -103,232,310.4 | -60,349,631.87 | 4,572,082.42 | 206,552,477.7 |
| 加:投资收益 | 21,026,636.05 | -6,789,402.25 | 49,428,681.35 | -4,987,597.19 |
| 资产处置收益 | -3,759.71 | 16,498.92 | 5,476,467.27 | 2,535,897.78 |
| 资产减值损失(新) | -2,244,215.45 | -1,210,601.79 | -436,991,981.1 | -7,665,953.46 |
| 信用减值损失(新) | 40,639,513.19 | 17,759,826.07 | -114,849,587.34 | -172,301,387.88 |
| 其他收益 | 15,586,801.78 | 6,997,382.46 | 36,263,375.45 | 27,603,870.23 |
| 四、营业利润 | -135,292,257.47 | -99,292,949.03 | -753,353,917.63 | -165,399,620.81 |
| 加:营业外收入 | 3,514,065.08 | 17,089.07 | 3,977,735 | 2,459,191.88 |
| 减:营业外支出 | 820,073.76 | 568,973.54 | 7,612,307.63 | 6,632,875.71 |
| 五、利润总额 | -132,598,266.15 | -99,844,833.5 | -756,988,490.26 | -169,573,304.64 |
| 减:所得税费用 | -8,132,312.88 | -1,648,679 | 23,533,470.39 | -18,798,396.95 |
| 六、净利润 | -124,465,953.27 | -98,196,154.5 | -780,521,960.65 | -150,774,907.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -124,465,953.27 | -98,196,154.5 | -780,521,960.65 | -150,774,907.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -120,386,063.78 | -98,154,811.55 | -744,378,901.74 | -141,504,567.19 |
| 少数股东损益 | -4,079,889.49 | -41,342.95 | -36,143,058.91 | -9,270,340.5 |
| 扣除非经常损益后的净利润 | -51,850,457.66 | -43,813,851.26 | -772,039,126.65 | -324,683,164.12 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.09 | -0.07 | -0.53 | -0.1 |
| (二)稀释每股收益 | -0.09 | -0.07 | -0.53 | -0.1 |
| 八、其他综合收益 | -140,260.15 | -158,233.04 | 1,447,181.54 | -521,826.97 |
| 归属于母公司股东的其他综合收益 | 61,588.62 | -40,338.04 | 1,569,502.22 | -430,784.58 |
| 九、综合收益总额 | -124,606,213.42 | -98,354,387.54 | -779,074,779.11 | -151,296,734.66 |
| 归属于母公司股东的综合收益总额 | -120,324,475.16 | -98,195,149.59 | -742,809,399.52 | -141,935,351.77 |
| 归属于少数股东的综合收益总额 | -4,281,738.26 | -159,237.95 | -36,265,379.59 | -9,361,382.89 |
| 公告日期 | 2026-08-29 | 2026-04-28 | 2026-04-28 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |